Skip to content
Moojaz — موجز
Search
Menu
HomeRegionsMaghrebAfricaMiddle EastEuropeAsiaAmericasWorldSectionsPoliticsEconomySecurityHealthScienceTechnologyAIEnvironmentCultureSportsSearch
What happened next?Continue in this file · Laprophan secures AMMC prospectus approval for IPO worth up to MAD 2.22 billion
File · Laprophan secures AMMC prospectus approval for IPO worth up to MAD 2.22 billion
Reported information

Laprophan management withholds Polymedic purchase-price details pending competition review

In an AlphaBourse article published on 29 October 2026, Laprophan management declined to detail the price of buying Polymedic’s parent company while the transaction is before the Competition Council.

Moroccan dirham, monetary illustration.
Monetary illustration from 2021; it does not depict the transaction or laboratories. Maroc 2022, CC BY-SA 4.0. — Maroc 2022 / Wikimedia Commons — CC BY-SA 4.0 https://creativecommons.org/licenses/by-sa/4.0/ — 21 décembre 2021, sans modification.

The prospectus earmarks nearly 90% of the planned capital increase for the acquisition, about MAD 1.26 billion out of MAD 1.4 billion. That financing allocation alone does not establish the final transaction price.

The contract concerns Corporate Investment Holding, Polymedic’s parent. Completion remains subject to the necessary approvals: neither competition clearance nor completion of the acquisition is established.

Sources 3
What happened before?Continue in this file · Laprophan secures AMMC prospectus approval for IPO worth up to MAD 2.22 billion